The agenda is subject to change as priorities dictate.

This meeting is open to the public, but without a public comment period. In the event an individual wishes to provide comments, written comments may be submitted. Any written comments received will be provided at the meeting and should be submitted to the contact person below in advance of the meeting.

**Contact Person for More Information:**

Theodore Katz, Executive Secretary, NIOSH, CDC, 1600 Clifton Road, Mailstop E–20, Atlanta, Georgia 30333, Telephone: (513) 533–6800, Toll Free: 1(800) CDC–INFO, E-mail oucas@cdc.gov.

The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry.

Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

**[FR Doc. 2010–4890 Filed 3–8–10; 8:45 am](#)**

**BILLING CODE 4163–18–P**

### DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### National Institutes of Health

**National Institute of Nursing Research; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Institute of Nursing Research, Special Emphasis Panel, NINR Loan Repayment Program Review (L30/L40).

**Date:** March 29, 2010.

**Time:** 9 a.m. to 12 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** National Institutes of Health, One Democracy Plaza, 6701 Democracy Boulevard, Ste. 710, Bethesda, MD 20892. (Telephone Conference Call)

**Contact Person:** Mario Rinaudo, MD, Scientific Review Administrator, Office of Review, National Institute of Nursing Research, National Institutes of Health, 6701 Democracy Blvd (DEM 1), Suite 710, Bethesda, MD 20892, 301–594–5973, mrinaudo@mail.nih.gov.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

(Catalogue of Federal Domestic Assistance Program Nos. 93.361, Nursing Research, National Institutes of Health, HHS)

**Dated:** March 1, 2010.

Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy.

**[FR Doc. 2010–4753 Filed 3–8–10; 8:45 am](#)**

**BILLING CODE 4140–01–M**

### DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### National Institute on Alcohol Abuse and Alcoholism; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Institute on Alcohol Abuse and Alcoholism Special Emphasis Panel; Review of Alcohol Resource Grant Applications.

**Date:** April 6, 2010.

**Time:** 2 p.m. to 6 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** National Institutes of Health, 5635 Fishers Lane, Bethesda, MD 20892. (Telephone Conference Call)

**Contact Person:** Richard A Rippe, Ph.D., Scientific Review Officer, National Institute on Alcohol Abuse & Alcoholism, National Institutes of Health, 5635 Fishers Lane, Rm. 2109, Rockville, MD 20852, 301–434–8599, ripper@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.271 Alcohol Research Career Development Awards for Scientists and Clinicians; 93.272, Alcohol National Research Service Awards for Research Training; 93.273, Alcohol Research Programs; 93.891, Alcohol Research Center Grants; 93.701, ARRA Related Biomedical Research and Support Awards, National Institutes of Health, HHS)

**Dated:** March 1, 2010.

Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy.

**[FR Doc. 2010–4753 Filed 3–8–10; 8:45 am](#)**

**BILLING CODE 4140–01–M**

### DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### Food and Drug Administration

**CIBA Vision Corp.; Withdrawal of Color Additive Petitions**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing the withdrawal, without prejudice to a future filing, of three color additive petitions (CAP 5C0278, CAP 5C0279, and CAP 5C0280) proposing that the color additive regulations be amended to provide for the safe use of Color Index (C.I.) Pigment Violet 19, C.I. Pigment Yellow 154, and C.I. Pigment Red 122 as color additives in contact lenses.

**FOR FURTHER INFORMATION CONTACT:** Celeste Johnston, Center for Food Safety and Applied Nutrition (HFS–265), Food and Drug Administration, 5100 Paint Branch Pkwy., College Park, MD 20740–3835, 301–436–1282.

**SUPPLEMENTARY INFORMATION:** In a notice published in the Federal Register of August 17, 2005 (70 FR 48426), FDA announced that three color additive petitions had been filed by CIBA Vision Corp., 11460 Johns Creek Pkwy., Duluth, GA 30097–1556. The petitions proposed to amend the color additive regulations in Part 73 Listing of Color Additives Exempt from Certification (21 CFR part 73) to provide for the safe use of C.I. Pigment Violet 19 (CAP 5C0278, Docket No. FDA–2005–C–0245), C.I. Pigment Yellow 154 (CAP 5C0279, Docket No. FDA–2005–C–0416), and C.I. Pigment Red 122 (CAP 5C0280, Docket No. FDA–2005–C–0504) as color additives in contact lenses. CIBA Vision Corp. has now withdrawn the petitions without prejudice to a future filing (21 CFR 71.6(c)(2)).